In a recent transaction on May 29, 2024, Mohsen Moazami, a director at Marpai, Inc. (NASDAQ:MRAI), sold 15,000 shares of the company's Class A Common Stock at an average price of $0.6788 per share, totaling approximately $10,182. Following the sale, Moazami's direct holdings in Marpai, Inc. amount to 35,000 shares.
The transaction was publicly disclosed through a Form 4 filing with the Securities and Exchange Commission. The sale took place amid the ordinary course of business on the stated date, with the reported price per share reflecting the average value at which the stock was sold.
Marpai, Inc., a company operating in the miscellaneous health and allied services sector, is incorporated in Delaware and has its business address in Tampa, Florida. The company's stock is traded on the NASDAQ stock exchange under the ticker symbol MRAI.
Investors often monitor insider transactions as they can provide insights into how the company's executives and directors view the stock's value and future performance. However, such transactions can occur for various reasons and may not necessarily indicate the executive's outlook on the company's future.
The details of the transaction, including the number of shares sold and the remaining ownership stake, are now part of the public record, providing transparency to investors and allowing them to consider this information in their investment decisions.
InvestingPro Insights
As investors digest the recent insider transaction by Mohsen Moazami, a director at Marpai, Inc., it's crucial to look at the company's financial health and market performance for a broader context. According to InvestingPro, Marpai's market capitalization stands at $9.28 million, reflecting a relatively small player in the miscellaneous health and allied services sector.
An analysis of Marpai's performance over the last twelve months as of Q1 2024 shows a notable revenue growth of 25.45%, indicating a positive trajectory in the company's ability to increase sales. However, this growth contrasts with a quarterly revenue decline of 23.65% in Q1 2024, suggesting potential volatility or seasonal impacts on the company's financial performance.
The company's gross profit margin stands at a healthy 34.89%, which is a strong indicator of Marpai's ability to manage its cost of goods sold effectively. Despite this, Marpai's operating income margin is reported at -62.85%, and the company's adjusted operating income is a significant loss of $21.91 million, signaling that expenses might be outweighing revenue, impacting overall profitability.
InvestingPro Tips highlight that Marpai's current P/E ratio is -0.64, and its PEG ratio is -0.01, which could indicate the stock is undervalued relative to its earnings growth. For investors seeking additional insights, there are more InvestingPro Tips available, and they can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
The recent insider sale might raise questions among investors, especially when considering Marpai's current price is at 17.63% of its 52-week high. The company's fair value, as per InvestingPro, is estimated at $2.28, which is significantly higher than the previous close price of $0.90. This discrepancy could suggest a potential undervaluation of Marpai's stock, offering an opportunity for investors to explore.
For those interested in a deeper dive into Marpai's financials and performance metrics, InvestingPro provides a comprehensive array of additional tips to aid in investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.